NCT00513435 · OUTCOME

Overall Survival

Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer · Source last updated 2014-04-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Days
Interval / dispersion: Full Range
Time frame: Up to 12 weeks

What was measured

The Kaplan-Meier method will be used to estimate overall survival.

Groups in this outcome

Treatment (Enzyme Inhibitor Therapy)

Patients receive saracatinib PO or by PEG tube QD on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Enzyme Inhibitor Therapy)	9

Reported measurements

Source class 1

Values in Days · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Treatment (Enzyme Inhibitor Therapy)	180	Not reported	27	1605	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
27
upper Limit
1605
value
180

denoms

counts
group Id
OG000
value
9
units
Participants

description

The Kaplan-Meier method will be used to estimate overall survival.

dispersion Type

Full Range

groups

description
Patients receive saracatinib PO or by PEG tube QD on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
id
OG000
title
Treatment (Enzyme Inhibitor Therapy)

param Type

MEDIAN

reporting Status

POSTED

time Frame

Up to 12 weeks

title

Overall Survival

type

SECONDARY

unit Of Measure

Days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice